Heparin increases human gastric carcinoma cell growth

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 439-443

  Wu, William Ka Kei ^a   Shin, Vivian Yvonne ^a   Ye, Yi Ni ^a   Wong, Helen Pui Shan ^a   Huang, Fung Yu ^a   Hui, Marco King Cheung ^a   Lam, Emily Kai Yee ^a   Cho, Chi Hin ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

c Myc; Cyclooxygenase; Epidermal growth factor receptor; Gastric cancer; Heparin

Indexed keywords

CYCLOOXYGENASE 2; HEPARIN; MESSENGER RNA; MYC PROTEIN; THYMIDINE;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STOMACH; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; THROMBOEMBOLISM; UPREGULATION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HEPARIN; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 32144440130     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D and Poller L: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108: 258S-75S, 1995.
2. Majerus PW, Broze GJ Jr, Miletich JP and Tollefsen DM: Anticoagulant, thrombolytic, and antiplatelet drugs. In: Goodman & Gillman's The Pharmacological Basis of Therapeutics, 9th ed. Hardman JG, Gilman AG and Limbard L (eds.). New York, McGraw Hill. pp. 1341-1359, 1996.
3. Kakkar AK: Thrombosis and cancer. Hematol J 5(Suppl 3): S20-S23, 2004.
4. Cervera A, Justicia C, Reverter JC, Planas AM and Chamorro A: Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat. J Neurosci Res 77: 565-572, 2004.
5. Elsayed E and Becker RC: The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 15: 11-18, 2003.
6. Mason HR, Nowak RA, Morton CC and Castellot JJ Jr: Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Am J Pathol 162: 1895-1904, 2003.
7. Carroll L and Koch J: Heparin stimulates production of bFGF and TGF-beta 1 by human normal, keloid, and fetal dermal fibroblasts. Med Sci Monit 9: BR97-BR108, 2003.
8. Li Y, Wang HY and Cho CH: Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. J Pharmacol Exp Ther 290: 789-796, 1999.
9. Li Y, Mei QB and Cho CH: Healing effects of heparin on acetic acid-induced gastric ulcers in rats. Chin Med J (Engl) 111: 12-16, 1998.
10. Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 50: 767-777, 2000.
11. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ and Ristimaki A: Cyclooxygenase-2 and gastric carcinogenesis. APMIS 111: 915-925, 2003.
12. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K and Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75: 1418-1425, 1995.
13. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J and Eilers M: Direct induction of Cylin D2 by myc contributes to cell cycle progression and sequestration of p27. EMBO J 18: 5321-5331, 1999.
14. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H and Hori M: Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94: 451-455, 1999.
15. Yamagishi M, Noda M, Tatsumi Y, Mukaisho K, Mitsufuji S, Sugihara H, Okanoue T and Hattori T: Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer. J Gastroenterol 39: 1143-1149, 2004.
16. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J and Wong BC: Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95: 1784-1791, 2003.
17. Garcia I, Vizoso F, Andicoechea A, Raigoso P, Verez P, Alexandre E, Garcia-Muniz JL and Allende MT: Clinical significance of epidermal growth factor receptor content in gastric cancer. Int J Biol Markers 16: 183-188, 2001.
18. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ and Ellis LM: ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3: 1041-1048, 2004.
19. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
20. Dimitriadou V and Koutsilieris M: Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 17: 1541-1549, 1997.
21. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M and Okamoto S: Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 2: 26-32, 1999.
22. Venkataraman G, Sasisekharan V, Herr AB, Ornitz DM, Waksman G, Cooney CL, Langer R and Sasisekharan R: Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA 93: 845-850, 1996.
23. Lyon M, Deakin JA and Gallagher JT: The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J Biol Chem 277: 1040-1046, 2002.
24. Suh J and Rabson AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117, 2004.
25. Grumont R, Lock P, Mollinari M, Shannon FM, Moore A and Gerondakis S: The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 21: 19-30, 2004.
26. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC and Luo J: Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobacter pylori cagA (+) infection. World J Gastroenterol 10: 491-496, 2004.
27. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J and Hondermarck H: The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 24: 5482-5485, 2005.
28. Tang JB, Xu Y, Ding F and Wang XT: Tendon healing in vitro: promotion of collagen gene expression by bFGF with NF-kappaB gene activation. J Hand Surg [Am]. 28: 215-220, 2003.
29. Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Matsumura Y, Habu S and Johnson AC: p53 homologue p63 represses epidermal growth factor receptor expression. J Biol Chem 276: 417-424, 2001.
30. Ishikawa Y and Kitamura M: Inhibition of glomerular cell apoptosis by heparin. Kidney Int 56: 954-963, 1999.
31. Weigert C, Brodbeck K, Haring HU, Gambaro G and Schleicher ED: Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 60: 935-943, 2001.
32. Ruan Y, Wu Z and Ivankovic S: The relationship between mast cell infiltration and the expression of PCNA and EGFr in experimental hepatocellular carcinoma of liver and squamous cell carcinoma of stomach in rats. J Tongji Med Univ 16: 6, 1996.